---
title: "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO"
description: "Pomerantz Law Firm is investigating claims on behalf of investors of NeoGenomics, Inc. (NASDAQ: NEO) regarding potential securities fraud by the company and its officers. NeoGenomics reported disappoi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253355716.md"
published_at: "2025-08-17T15:15:31.000Z"
---

# INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO

> Pomerantz Law Firm is investigating claims on behalf of investors of NeoGenomics, Inc. (NASDAQ: NEO) regarding potential securities fraud by the company and its officers. NeoGenomics reported disappointing Q2 2025 financial results, with revenue of $181.3 million and a net loss of $45.1 million, leading to a stock price drop of 18.73% to $5.25 per share. The firm is known for its expertise in securities class actions and has a history of recovering damages for victims of corporate misconduct.

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**\[Click here for information about joining the class action\]**

July 29, 2025, NeoGenomics issued a press release reporting its financial results for the second quarter of 2025. Among other items, NeoGenomics reported revenue of $181.3 million, falling short of consensus estimates, and a net loss of $45.1 million. NeoGenomics also reduced its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million. In addition, NeoGenomics lowered its adjusted EBITDA projection to a range of $41 million to $44 million from a prior range of $55 million to $58 million.

On this news, NeoGenomics’ stock price fell $1.21 per share, or 18.73%, to close at $5.25 per share on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**  
Danielle Peyton  
Pomerantz LLP  
dpeyton@pomlaw.com  
646-581-9980 ext. 7980

### Related Stocks

- [NEO.US - Neogenomics](https://longbridge.com/en/quote/NEO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NeoGenomics 推出 PanTracer Pro，以支持及时且知情的实体瘤治疗选择 \| NEO 股票新闻 | NeoGenomics, Inc.推出了 PanTracer Pro，这是一种新的综合测试方法，旨在改善晚期实体肿瘤患者的治疗选择。该解决方案将全面的基因组分析与诊断导向的免疫组化相结合，简化了测试过程并减少了诊断的不确定性。测试结果预计在 | [Link](https://longbridge.com/en/news/275753736.md) |
| Neogenomics｜8-K：2025 财年 Q4 营收 1.9 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/272266327.md) |
| 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| 奔驰中国换帅，告别 “段建军时代” | 首位本土高管身退。 | [Link](https://longbridge.com/en/news/275976978.md) |
| 市场监管总局约谈阿里巴巴、抖音、百度、腾讯、京东、美团、淘宝闪购等平台企业 | 市场监管总局于 2 月 13 日约谈了阿里巴巴、抖音、百度、腾讯、京东、美团和淘宝闪购等平台企业，要求它们遵守相关法律法规，落实主体责任，规范促销行为，并杜绝 “内卷式” 竞争，以维护公平竞争市场环境，促进平台经济的创新与健康发展。 | [Link](https://longbridge.com/en/news/275975190.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.